Transcription-independent expression of PKMζ in the anterior cingulate cortex contributes to chronically maintained neuropathic pain

Hyoung-Gon Ko1, Sanghyun Ye1, Dae-Hee Han1, Pojeong Park1, Chae-Seok Lim2, Kyungmin Lee3, Min Zhuo4,5, and Bong-Kiun Kaang1,5

Abstract
Protein kinase Mζ is well known for its role in maintaining memory and pain. Previously, we revealed that the activation of protein kinase Mζ in the anterior cingulate cortex plays a role in sustaining neuropathic pain. However, the mechanism by which protein kinase Mζ is expressed in the anterior cingulate cortex by peripheral nerve injury, and whether blocking of protein kinase Mζ using its inhibitor, zeta inhibitory peptide, produces analgesic effects in neuropathic pain maintained chronically after injury, have not previously been resolved. In this study, we show that protein kinase Mζ expression in the anterior cingulate cortex is enhanced by peripheral nerve injury in a transcription-independent manner. We also reveal that the inhibition of protein kinase Mζ through zeta inhibitory peptide treatment is enough to reduce mechanical allodynia responses in mice with one-month-old nerve injuries. However, the zeta inhibitory peptide treatment was only effective for a limited time.

Keywords
Protein kinase Mζ, neuropathic pain, anterior cingulate cortex, chronic pain

Introduction
The question of how memory is permanently stored even though the physical traces of memory such as synaptic connections are not permanent had not been solved. An atypical protein kinase C (PKC) isoform, protein kinase Mζ (PKMζ), has recently emerged as the answer to this question.1–4 This kinase has the unique property that it lacks a regulatory subunit. Thus, PKMζ is constitutively active once it is expressed and this feature enables this kinase to maintain memory.5 PKMζ is necessary and sufficient for maintaining long-term potentiation (LTP) and many kinds of memories. Blocking of PKMζ using zeta inhibitory peptide (ZIP) disrupts hippocampal LTP after the induction phase.1,6 Several types of memories such as fear, spatial, and taste aversion memories can be erased by ZIP treatment to the hippocampus, amygdala, and insular cortex.2,5,7,8 At the molecular level, PKMζ maintains memory by keeping GluA2-containing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) in the postsynaptic density (PSD) regions.9–11
Neuropathic pain induced by peripheral nerve injury can lead to LTP-like changes in the anterior cingulate cortex (ACC), a brain region known to be involved in affective dimension of pain. The mechanism of LTP maintenance is thought to be fairly universal in the brain. Based on this similarity, we previously hypothesized that PKMζ in the ACC could mediate the maintenance of neuropathic pain and showed that peripheral nerve injury enhances the PKMζ expression in the ACC. We also revealed that the inhibition of PKMζ in the ACC can lead to LTP-like changes in the ACC. Intriguingly, PKMζ in the ACC sustains GluA1-containing AMPAR in the PSD region. However, it has not been clearly elucidated whether ZIP is effective for treating neuropathic pain that is chronically maintained. It is also important to investigate how long the effects of ZIP continue after a single treatment.

In this study, we examined whether LTP or long-term depression (LTD) stimulation of the ACC leads to PKMζ activation. We also measured the level of PKMζ mRNA in the ACC after peripheral nerve injury. In addition, we investigated the effect of ZIP on neuropathic pain induced one month prior to treatment and evaluated the duration of the effect of single ZIP treatments to the ACC.

Materials and methods

Animals

Male wild-type C57BL/6NCrjBgi mice (6–10 weeks old) were purchased from Orient Bio. The mice were maintained in a 12-h light/dark cycle. Food and water were provided ad libitum. All experiments were conducted according to the guidance of the Institutional Animal Care and Use Committee of Seoul National University.

Cannula implantation and drug infusion

Guide cannulas (24 gauge) were implanted bilaterally into the ACCs of mice (+0.7 mm, ±0.4 mm, and −1.7 mm) anesthetized with a ketamine/xylazine mixture. The mice were given at least one week to recover after cannula implantation. A 30-gauge injection cannula was then implanted 0.2 mm lower than the guide. For the intra-ACC infusion, 0.5 μl ZIP (10 nmol/μl) or actinomycin D (ActD) (20 ng/μl) or vehicle was delivered bilaterally within 1 min and the cannula remained for an additional 1 min after the drug microinfusion was completed. After all experiments were completed, the mice brains were processed to assess the injection site. Mice that were cannulated outside of the ACC were excluded from the analysis.

Neuropathic pain surgery

Mice were anesthetized with a ketamine/xylazine mixture (5.9:1) in saline. Their eyes were protected by artificial tear jelly or saline. The left leg of each mouse was shaved using scissors and sterilized with a 70% alcohol and povidone iodine liquid. About 1 cm of the left thigh skin was cut, exposing the muscles. An incision was made in the muscle using scissors, and sterile saline was applied to the exposed region. Next, the common peroneal nerve (CPN) was ligated with a wax-coated braided silk suture 4–0 without disturbing or including the blood vessel. The ligature was slowly tightened until twitching of the dorsiflexors of the foot became visible at the digit. After making a knot, the skin was sutured using a 5–0 silk suture and cleaned with povidone iodine liquid. In a few cases, the mice did not show any allodynia response three days after CPN ligation. These mice were therefore excluded from further experiments.

Measurement of mechanical alldynia response

Mechanical alldynia responses were measured essentially as described previously. The mice were placed in individual cylinders and allowed to acclimatize for 1 h prior to testing. Mechanical alldynia was assessed based on the responsiveness of the hind paw to the application of a von Frey filament to the point of bending. Positive responses included licking, biting, and sudden withdrawal of the hind paw. Mechanical pressure from a 1.65 filament (force, 0.008 g) was used to test the mice’s mechanical alldynia nine times with inter-trial intervals of 5 min. The animals were then permitted to rest for 2 h after drug infusion, and their mechanical alldynia was retested. All behavioral experiments were performed by a blind experimenter.

Subcellular fractionation for PSD fraction

The purification of PSD fraction was performed essentially as described previously. The CPN-ligated mice were anesthetized and decapitated 2 h after ZIP infusion. Three slices (400 μm) of the ACC region near the infusion site were collected per mouse. Six of the ACC slices were used for fractionation. Briefly, the slices were homogenized in Frac buffer (30 mM pH 7.4 Tris-Cl, 4 mM EDTA, and 1 mM EGTA) containing a protease inhibitor cocktail. The homogenates were centrifuged at 500 g, at 4°C for 5 min, twice, to remove the nucleus fraction and debris. The supernatants were centrifuged at 100,000 g for 1 h at 4°C, and the pellet was lysed using Frac buffer containing 0.5% Triton X-100 and a protease inhibitor cocktail. After incubation for 20 min on ice, the lysates were carefully loaded onto the surface of 1 M sucrose and then centrifuged at 100,000 g for 1 h at 4°C.
The pellet (PSD fraction) was used for blotting after which it had been lysed using PSD lysis buffer (1 M pH 7.4 HEPES, 5 M NaCl, 10% Triton X-100, 10% sodium deoxycholate, 10% sodium dodecyl sulfate (SDS), and 100 mM DTT) containing the protease inhibitor cocktail.

**Western blot analysis**

Western blot was performed essentially as described previously. The mice were lightly anesthetized with isoflurane and then decapitated. The region of the ACC (400 μm thickness slice, three slices per mouse) was dissected and then homogenized in RIPA buffer (50 mM pH 7.6 Tris-Cl, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 1 mM DTT, 0.5% sodium deoxycholate) containing a protease inhibitor cocktail and protein phosphatase inhibitor cocktail after glycine treatment (30 min) and washout (60 min). After centrifugation, the supernatants were used for protein quantification by Bradford assay. Electrophoresis of equal amounts of total protein was performed on 4%–12% SDS-polyacrylamide gels (Invitrogen). The separated proteins were transferred onto a nitrocellulose membrane and stored at 4°C overnight. After blocking with 3% skim milk (for actin) or 5% skim milk (for PKMε) overnight, the membranes were incubated with PKMε (1:500, Invitrogen), phosphor-PKCζ (1:1000, Cell Signaling), GluA2 (1:1000, Abcam), or actin (1:5000, Sigma) primary antibody at 4°C overnight. After washing, the membranes were treated with a horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature, followed by enhanced chemiluminescence detection of the proteins according to the manufacturer’s instructions. The density of immunoblots was measured and analyzed using ChemiDoc™ MP System (Bio-Rad).

**Quantitative real-time PCR**

Quantitative real-time PCR was performed essentially as described previously. To measure mRNA expression level in the ACC after nerve injury, the region of the ACC (400 μm thickness slice, three slices per mouse) was dissected. Total RNA was purified with Trizol (Invitrogen) or RNAiso plus (Takara) reagent according to the user’s manual. After DNase I treatment for 15 min at room temperature, purified RNA was used for cDNA synthesis prepared by the SuperScript™ III First-Strand Synthesis System for RT-PCR (Cat. #18080–051, Invitrogen). After phenol/chloroform extraction and ethanol precipitation, cDNA was used for quantitative real-time PCR. To compare PKMε mRNA levels between the sham and nerve injury groups, quantitative real-time PCR was performed using SYBR Premix Ex Taq II (Cat. #RR820A, Takara) in a CFX96 Real-Time PCR Detection System according to the user’s manual. The primers for PKMε are 5’-ACGCCACCTCGGTAGAGC-3’ for forward and 5’-GGACGTGGACGGTTATGG-3’ for reverse. The primers for brain-derived neurotrophic factor (BDNF) are 5’-AGTGAATCCCATGGTTACACCA-3’ for forward and 5’-CAGGAAGTGTC ATCTTATGAA TTC-3’ for reverse. The primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) are 5’T-GGACGTGGACGGTTATGG-3’ for forward and 5’-GGATGCAGGGATGATGTTTC-3’ for reverse. The expression level of PKMε or BDNF was normalized to the expression level of GAPDH as a reference gene.

**LTP recording using MED64**

Mice were anesthetized with isoflurane and killed by decapitation. The brain was removed and then quickly placed in ice-cold, oxygenated (95% O2, 5% CO2) cutting solution containing (in mM) 124 NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 10 MgSO4, 15 Glucose, and 2 CaCl2. Coronal slices (300 μm) of the ACC were prepared using a vibratome (Leica VT 1000S). Those slices were allowed to recover in oxygenated artificial cerebrospinal fluid (aCSF) at 26°C for at least 2h before recordings were performed. aCSF contained the following (in mM): 124 NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 10 MgSO4, 15 Glucose, and 2 CaCl2. Multielectrode array system (Panasonic, MED64) was used to record extracellular field excitatory postsynaptic potentials (fEPSP) slopes in the ACC as reported previously. Briefly, the MED64 probe was perfused with oxygenated aCSF at a rate of 2–3 ml/min and maintained at 28–30°C. One planar microelectrode with monopolar constant-current pulses (5–18 μA, 0.2ms) was used for stimulation of the ACC slice. Electrical stimulation was delivered to a microelectrode of the MED64 probe which is located within the deep layer V region of ACC. Evoked fEPSP slope was recorded in the other 63 microelectrodes. The stimulation intensity was determined to obtain stable responses from 4 to 6 microelectrodes near the stimulation site. One coronal slice was transferred to MED64 probe and allowed to recover for 30 min before recordings were initiated. Electrical stimulation was delivered at a frequency of 0.02 Hz. Following 30 min of stable baseline recording, glycine (1 mM) was applied for 30 min and washed out for another 1 h. For every slice, 4–6 channels near stimulation sites were chosen to be analyzed because of their stable response. The averaged value of those channels was counted as one sample and the data were averaged every 5 min. Glycine was purchased from Tocris Bioscience and prepared as a frozen stock solution.
(stored below −20°C) and dissolved into aCSF at least 30 min before their bath application.

**Data analysis**

Statistical comparisons were made using unpaired or paired t-tests or one-way ANOVAs. All data were presented as the mean ± SEM. In all cases, p < 0.05 was considered as statistically significant.

**Results**

It has been reported that LTP stimulation enhances PKMζ and p-PKMζ levels in hippocampal slices. Thus, we tested whether LTP stimulation also activates PKMζ in the ACC. To induce chemical LTP, ACC slices were treated with 1 mM glycine for 30 min and incubated for 1 h after being rinsed. Consistent with previous findings, this protocol induced LTP for 1 h after the glycine washout (Figure 1(a)). The p-PKMζ expression

---

**Figure 1.** Enhancement of PKMζ induced by chemical LTP and transcription-independent increases of PKMζ induced by peripheral nerve injury. (a) Bath application of 1 mM glycine for 30 min induced LTP after washout (n = 6 slices/5 mice). (b) Western blot for PKMζ and p-PKMζ using slices treated with 1 mM glycine. To induce chemical LTP, the slices were treated with 1 mM glycine for 30 min and then washed out. One hour after washout, the ACC regions were used for Western blot experiments (PKMζ: control: 100.0 ± 2.6%, glycine: 133.6 ± 16.9%, n = 6–8, p = 0.09, p-PKMζ: control: 100.0 ± 6.9, glycine: 147.3 ± 17.9%, n = 5–6, unpaired t-test; *p < 0.05). (c) Glycine treatment significantly reduced PKMζ mRNA levels (CTL: 1.000 ± 0.08167%, Gly: 0.8115 ± 0.04356%, n = 6, unpaired t-test; **p < 0.01). (d) Western blot for PKMζ and p-PKMζ using slices treated with DHPG. To induce chemical LTD, the slices were treated with 10, 50, or 100 μM DHPG for 30 min and then washed out. One hour after washout, the ACC regions were used for Western blot experiments (n = 4 per group, one-way ANOVA; p > 0.05). (e) The mRNA level of PKMζ in the ACC at three days after nerve injury. GAPDH was used as the internal control (upper panel). The PKMζ mRNA level was not different between the control and nerve injury groups (lower panel; n = 10–11 per group, unpaired t-test; p > 0.05). (f) Peripheral nerve injury increased the PKMζ protein level in the ACC. However, ActD treatment in the ACC did not reverse the nerve injury-induced increase in PKMζ protein levels (Sham + veh: 100 ± 9.403%, NI + veh: 157.3 ± 10.50%, NI + ActD: 143.3 ± 10.33%, n = 8–9 mice per group, p < 0.01, one-way ANOVA followed by Tukey’s multiple comparisons post hoc test. *p < 0.05; **p < 0.01). (g) ActD pretreatment in the ACC blocked the increase in BDNF mRNA level 90 min after formalin injection. GAPDH was used as the internal control. Formalin (5%, 10 μl) was injected into the left paw 30 min after ActD microinjection in the ACC. The ACC was then dissected 90 min after formalin injection. The BDNF mRNA level differed between the groups (n = 3 per group, one-sample t-test; *p < 0.05). CTL: control; PKMζ: protein kinase Mζ; Gly: glycine; DHPG: dihydroxyphenylglycine; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; veh: vehicle; ActD: actinomycin D; NI: nerve injury.
was enhanced by chemical LTP stimulation, although PKMζ level showed a tendency to increase (Figure 1(b)). However, the PKMζ mRNA level was significantly reduced after glycine treatment (Figure 1(c)). Next, we tested whether LTD also affects PKMζ activation in the ACC. However, mGluR-dependent LTD stimulation induced by several doses of dihydroxyphenylglycine bath-application for 30 min did not affect the level of PKMζ and p-PKMζ in the ACC (Figure 1(d)). Given that peripheral nerve injury such as amputation can induce an LTP-like state in the ACC, these results imply that nerve injury induces LTP and it may, then, enhance and activate PKMζ in the ACC in a transcription-independent manner.

We previously showed that cAMP signaling increased PKMζ expression within a short period of time. This result indicates a transcription-independent expression of PKMζ, because transcription of PKMζ pre-mRNA is likely to take more than 30 min. To clarify this point, we tested the change of PKMζ mRNA in the ACC three days after nerve injury. As expected, the PKMζ mRNA level did not change significantly in the nerve injury group (Figure 1(e)), upper panel). Quantitative real-time PCR also showed no increase in PKMζ mRNA level in the ACC after nerve injury (Figure 1(e), lower panel). Moreover, treatment with the transcription inhibitor ActD did not block the increase in PKMζ protein level in the ACC four days after nerve injury (Figure 1(f)). The absence of an effect of ActD on PKMζ protein level was not due to the use of a low dose of ActD (10 ng/side, bilateral infusion), as this dose is sufficient to block the increase in BDNF mRNA level in the ACC of mice injected with formalin to induce acute inflammatory pain (Figure 1(g)). These results further support the idea that the increase in PKMζ level in the ACC induced by nerve injury was independent of transcription.

Inhibition of PKMζ using ZIP reduces allodynia responses shown in neuropathic pain. In the case of neuropathic pain, noxious signals from the peripheries are continuously delivered to various brain areas including the ACC region. Thus, it is useful to determine how long the alleviating effects of a single ZIP treatment for hyperalgesia last. Based on our previous result, we measured the mechanical allodynia response at 4 or 6 h after ZIP infusion into the ACC. As shown in Figure 2(a) and (b), there was still a noticeable analgesic effect after an interval of 4 h, but not at 6 h. As neuropathic pain is a type of chronic pain, it is necessary to evaluate the effect of ZIP on chronically maintained neuropathic pain in view of clinical trial. In a previous study, the effects of ZIP were tested in a neuropathic pain model that was 3 or 7 days old. Therefore, we tested the effects of ZIP on mice with nerve injuries induced one month before and found that ZIP still reduced the allodynia response in nerve-injured mice after one month (Figure 2(c) and (d)).

Our results shed some light on the synaptic mechanisms likely to be responsible for the analgesic effects produced by ZIP in neuropathic pain. PKMζ can post-synaptically potentiate the amplitude of AMPA receptor-mediated excitatory postsynaptic currents. Given that glutamatergic synaptic transmission in the ACC is increased after nerve injury, PKMζ may contribute to the maintenance of the enhanced synaptic transmission induced by nerve injury. Previously, we showed that ZIP infusion in the ACC reduced postsynaptic GluA1, one component of AMPARs, selectively in the nerve injury group. This result is surprising because previous studies have identified GluA2 as a target of PKMζ. Thus, we tested if GluA2 is also reduced by ZIP treatment in the ACC. However, there was no difference in GluA2 between the saline and ZIP-infused groups in nerve-injured mice (Figure 3). This result indicates that PKMζ exerts its effect through the GluA1 AMPAR subunit at synapses in the ACC.

**Discussion**

Here, we revealed that LTP, not LTD, stimulation activates PKMζ in the ACC. These enhancements in PKMζ and p-PKMζ are independent of transcription. The level of PKMζ mRNA in the ACC did not show enhancement after peripheral nerve injury. In addition, we confirmed that ZIP is still effective against mechanical allodynia maintained chronically in mice with neuropathic pain but only within a limited time. Although we did not observe the increase in PKMζ mRNA in the ACC three days after nerve injury, it does not mean that the expression of PKMζ is completely independent of transcription. It is plausible that PKMζ mRNA increases during a short time period after the initial peripheral nerve injury. Ongoing local cortical activity after nerve injury can activate adaptive mechanisms in the neurons of the ACC. Thus, to reveal the exact mechanism of PKMζ enhancement induced by nerve injury, it is necessary to measure the PKMζ mRNA level a relatively short time after nerve injury.

Most patients suffering from neuropathic pain have been afflicted for long time, rather than a short period. If ZIP is to be used as a medicine, it should show therapeutic effect in chronically maintained neuropathic pain. ZIP infusion into the ACC still reduces the mechanical allodynia response shown in neuropathic pain a month old (Figure 2(b)). Given that ZIP application into the ACC does not show any side effects such as memory deficits, this finding raises the possibility that ZIP could be used as a medication for chronic pain. However, the therapeutic effect of ZIP did not last for more than 4 h (Figure 2(a)). Therefore, it is necessary to
Figure 2. The duration of the effect of ZIP on neuropathic pain. (a) The experimental scheme for measuring the duration of ZIP effect. (b) Location of the cannula tip (upper panel). Allodynia response at 4 or 6 h after ZIP infusion into the ACC (lower panel). Mice with nerve injuries induced three days before the allodynia test were used in this experiment. On the test day, ZIP was infused into the ACC immediately after the allodynia response (pre) had been measured. Then, the allodynia response was measured again at 4 or 6 h after ZIP infusion (n = 4–5, paired t-test; *p < 0.05). (c) The experimental scheme for testing the analgesic effect of ZIP in mice with nerve injuries induced one month before. (d) Location of the cannula tip (upper panel). Allodynia response at 2 h after ZIP infusion into the ACC (lower panel). Mice with nerve injury induced one month before the allodynia test were used in this experiment. On the test day, ZIP was infused into the ACC immediately after the allodynia response (pre) had been measured. Then, the allodynia response was measured again at 2 h after infusion (n = 3–5 per group, unpaired t-test between saline and ZIP infusion group, paired t-test between “pre” and “2 h post infusion” in the ZIP infusion group; *p < 0.05). ZIP: zeta inhibitory peptide.

Figure 3. Inhibition of PKMζ in the ACC does not reduce postsynaptic GluA2 levels. (a) Representative image of Western blot. (b) The postsynaptic GluA2 level was not decreased at 2 h after ZIP infusion into the ACC. Mice with nerve injury induced three days earlier were used for this experiment (n = 4 per group, one-way ANOVA, p > 0.05). NI: nerve injury; veh: vehicle. ZIP: zeta inhibitory peptide; NI: nerve injury.
GluA1 is a target of PKMζ. Given that PKMζ regulates GluA2 subunit trafficking in the synapse, it is quite interesting that the inhibition of PKMζ did not reduce GluA2 in the PSD fraction of nerve-injured mice. This discrepancy might stem from brain region- or modality-specific functions of PKMζ. To date, GluA2 has been found to be a target of PKMζ because NSF does not directly bind to GluA1.31

To further explore the role of PKMζ in the brain, we examined whether PKMζ might be a target of PKMζ in the ACC of nerve-injured mice. This discrepancy might stem from brain region- or modality-specific functions of PKMζ. To date, GluA2 has been found to be a target of PKMζ because NSF does not directly bind to GluA1.31

Our previous finding that the GluA1, and not the GluA2, subunit is required for LTP in the ACC supports our present results because LTP in the ACC underlies chronic pain.32 Thus, it is valuable to investigate which target molecule of PKMζ in the ACC mediates GluA1 trafficking in the synapse to sustain chronic pain. These future studies will contribute to the development of new medicines for chronic pain.

Author Contributions
H-GK designed the study, carried out all the experiments, and outlined and wrote the manuscript. SY carried out all the experiments, and H-GK designed the study, carried out all the experiments, and outlined and wrote the manuscript. SY carried out all the experiments, and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
We are grateful to Hyunjun Jung and Yoonkey Nam at Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology for the technical help with MED64 probes.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by two National Research Foundation (NRF) of Korea grants funded by the Korean government (MSIP) [NRF-2012R1A3A1050385 to B-KK and 2018R1C1B6008530 to H-GK]. SY was supported by the BK21 Research Fellowship from the Ministry of Education, Science and Technology, Republic of Korea.

References
1. Ling DSF, Benardo LS, Serrano PA, Blace N, Kelly M T, Crary J F, Sacktor T C. Protein kinase Mzeta is necessary and sufficient for LTP maintenance. Nat Neurosci 2002; 5: 295–296.
2. Pastalkova E, Serrano P, Pinkhasova D, Wallace E, Fenton AA, Sacktor TC. Storage of spatial information by the maintenance mechanism of LTP. Science 2006; 313: 1141–1144.
3. Ko H-G, Kim J-I, Sim S-E, Kim THyun, Yoo J, Choi S-L, Baek S H, Yu W-J, Yoon J-B, Sacktor T C, Kaang B-K. The role of nuclear PKMzeta in memory maintenance. Neurobiol Learn Mem 2016; 135: 50–56.
4. Lisman J. Criteria for identifying the molecular basis of the engram (CaMKII, PKMzeta). Mol Brain 2017; 10: 55
5. Sacktor TC. How does PKMzeta maintain long-term memory? Nat Rev Neurosci 2011; 12: 9–15.
6. Serrano P, Yao Y and Sacktor TC. Persistent phosphorylation by protein kinase Mzeta maintains late-phase long-term potentiation. J Neurosci 2005; 25: 1979–1984.
7. Shema R, Sacktor TC and Dudai Y. Rapid erasure of long-term memory associations in the cortex by an inhibitor of PKM zeta. Science 2007; 317: 951–953.
8. Kwapis JL, Jerome TJ, Lonergan ME and Helmstetter FJ. Protein kinase Mzeta maintains fear memory in the amygdala but not in the hippocampus. Behav Neurosci 2009; 123: 844–850.
9. Yao Y, Kelly MT, Sajikumar S, Serrano P, Tian D, Bergold PJ, Frey JU, Sacktor TC. PKM zeta maintains late long-term potentiation by N-ethylmaleimide-sensitive factor/GluR2-dependent trafficking of postsynaptic AMPA receptors. J Neurosci 2008; 28: 7820–7827.
10. Migues PV, Hardt O, Wu DC, Gamache K, Sacktor TC, Wang YT and Nader K. PKMzeta maintains memories by regulating GluR2-dependent AMPA receptor trafficking. Nat Neurosci 2010; 13: 630–634.
11. Yu N-K, Uhm H, Shim J, Choi J-H, Bae S, Sacktor T C, Hohng S and Kaang B-K. Increased PKMzeta activity impedes lateral movement of GluA2-containing AMPA receptors. Mol Brain 2017; 10: 56.
12. Wei F and Zhuo M. Potentiation of sensory responses in the anterior cingulate cortex following digit amputation in the anaesthetised rat. J Physiol (Lond) 2001; 532: 823–833.
13. Kang S J, Kim S, Lee J, Kwak C, Lee K, Zhuo M and Kaang B-K. Inhibition of anterior cingulate cortex excitatory neuronal activity induces conditioned place preference in a mouse model of chronic inflammatory pain. Korean J Physiol Pharmacol 2017; 21: 487–493.
14. Bliss TV, Collingridge GL, Kaang BK and Zhuo M. Synaptic plasticity in the anterior cingulate cortex in...
acute and chronic pain. Nat Rev Neurosci 2016; 17: 485–496.
15. Kang S J, Kwak C, Lee J, Sim S-E, Shim J, Choi T, Collingridge GL, Zhuo M and Kaang B-K. Bidirectional modulation of hyperalgesia via the specific control of excitatory and inhibitory neuronal activity in the ACC. Mol Brain 2015; 8: 81.
16. Li X-Y, Ko H-G, Chen T, Descalzi G, Koga K, Wang H, Kim SS, Shang Y, Kwak C, Park S-W, Shim J, Lee K, Collingridge G L, Kaang B-K and Zhuo M. Alleviating neuropathic pain hypersensitivity by inhibiting PKMζeta in the anterior cingulate cortex. Science 2010; 330: 1400–1404.
17. Li XY, Ko HG, Chen T, Collingridge GL, Kaang BK and Zhuo M. Erasing injury-related cortical synaptic potentiation as a new treatment for chronic pain. J Mol Med 2011; 89: 847–855.
18. Radwanska K, Medvedev NI, Pereira GS, Engmann O, Thiede N, Moraes MFD, Villers A, Irvine EE, Maunganidze NS, Pyza EM, Ris L, Szymańska M, Lipiński M, Kaczmarek L, Stewart MG, Giese KP. Mechanism for long-term memory formation when synaptic strengthening is impaired. Proc Natl Acad Sci USA 2011; 108: 18471–18475.
19. Vadakkkan KI, Jia YH and Zhuo M. A behavioral model of neuropathic pain induced by ligation of the common peroneal nerve in mice. J Pain 2005; 6: 747–756.
20. Ko H-G, Choi J-H, Park DI, Kang SJJ, Lim C-S, Sim S-E, Shim J, Kim J-I, Kim S, Choi T-H, Ye S, Lee J, Park P, Kim S, Do J, Park J, Islam MA, Kim HJ, Turck CW, Collingridge GL, Zhuo M and Kaang B-K. Rapid turnover of cortical NCAM1 regulates synaptic reorganization after peripheral nerve injury. Cell Rep 2018; 22: 748–759.
21. Hwang KD, Bak MS, Kim SJ, Rhee S, Lee YS. Restoring synaptic plasticity and memory in mouse models of Alzheimer’s disease by PKR inhibition. Mol Brain 2017; 10: 57.
22. Yu N-K, Kim HF, Shim J, Kim S, Kim DW, Kwak C, Sim S-E, Choi J-H, Ahn S, Yoo J, Choi S-L, Jang D-J, Lim C-S, Lee Y-S, Kang C, Choi SY and Kaang B-K. A transducible nuclear/nucleolar protein, mLLP, regulates neuronal morphogenesis and synaptic transmission. Sci Rep 2016; 6: 22892.
23. Cho J, Yu N-K, Choi J-H, Sim S-E, Kang SJJ, Kwak C, Lee S-W, Kim J-I, Choi DI, Kim VN and Kaang B-K. Multiple repressive mechanisms in the hippocampus during memory formation. Science 2015; 350: 82–87.
24. Kang SJ, Liu M-G, Chen T, Ko H-G, Baek G-C, Lee H-R, Lee K, Collingridge GL, Kaang B-K and Zhuo M. Plasticity of metabotropic glutamate receptor-dependent long-term depression in the anterior cingulate cortex after amputation. J Neurosci 2012; 32: 11318–11329.
25. Kelly MT, Crary JF, Sacktor TC. Regulation of protein kinase Mζeta synthesis by multiple kinases in long-term potentiation. J Neurosci 2007; 27: 3439–3444.
26. Shang Y, Wang H, Mercaldo V, Li X, Chen T and Zhuo M. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J Neurochem 2009; 111: 635–646.
27. Hernandez AI, Blace N, Crary JF, Serrano PA, Leitges M, Libien JM, Weinstein G, Tcherapanov A and Sacktor TC. Protein kinase Mζeta synthesis from a brain mRNA encoding an independent protein kinase Cζeta catalytic domain. Implications for the molecular mechanism. J Biol Chem 2003; 278: 40305–40316.
28. Palmisano M, Caputi FF, Mercatelli D, Romualdi P and Candeletti S. Dynorphinergic system alterations in the corticostriatal circuitry of neuropathic mice support its role in the negative affective component of pain. Genes Brain Behav 2018; e12467.
29. Ling DS, Benardo LS, Sacktor TC. Protein kinase Mζeta enhances excitatory synaptic transmission by increasing the number of active postsynaptic AMPA receptors. Hippocampus 2006; 16: 443–452.
30. Xu H, Wu L-J, Wang H, Zhang X, Vadakkkan KI, Kim SS, Steenland HW and Zhuo M. Presynaptic and postsynaptic amplifications of neuropathic pain in the anterior cingulate cortex. J Neurosci 2008; 28: 7445–7453.
31. Nishimune A, Isaac JT, Molnar E, Noel J, Nash SR, Tagaya M, Collingridge GL, Nakanishi S, Henley JM. NSF binding to GluR2 regulates synaptic transmission. Neuron 1998; 21: 87–97.
32. Toyoda H, Zhao M-G, Ulzhöfer B, Wu L-J, Xu H, Seeburg PH, Sprengel R, Kuner R and Zhuo M. Roles of the AMPA receptor subunit GluA1 but not GluA2 in synaptic potentiation and activation of ERK in the anterior cingulate cortex. Mol Pain 2009; 5: 46.